Cargando…

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout, degradation or small molecule targeted-inhibition of GFI1/LSD1 on active enhancers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiskus, Warren, Mill, Christopher P., Nabet, Behnam, Perera, Dimuthu, Birdwell, Christine, Manshouri, Taghi, Lara, Bernardo, Kadia, Tapan M., DiNardo, Courtney, Takahashi, Koichi, Daver, Naval, Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Kornblau, Steven, Borthakur, Gautam, Montalban-Bravo, Guillermo, Manero, Guillermo Garcia, Sharma, Sunil, Stubbs, Matthew, Su, Xiaoping, Green, Michael R., Coarfa, Cristian, Verstovsek, Srdan, Khoury, Joseph D., Vakoc, Christopher R., Bhalla, Kapil N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138012/ https://www.ncbi.nlm.nih.gov/pubmed/34016956 http://dx.doi.org/10.1038/s41408-021-00487-3

Ejemplares similares

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

Targeting cistrome and dysregulated transcriptome of post-MPN sAML
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
por: Fiskus, Warren, et al.
Publicado: (2019)

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
por: Saenz, Dyana T., et al.
Publicado: (2016)

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
por: Saenz, Dyana T., et al.
Publicado: (2017)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2023)

P585: IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES
por: Senapati, Jayastu, et al.
Publicado: (2023)

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
por: Nguyen, Daniel, et al.
Publicado: (2023)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis
por: Shoukier, Mahran, et al.
Publicado: (2020)

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2022)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
por: Short, Nicholas J., et al.
Publicado: (2022)

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
por: Möröy, Tarik, et al.
Publicado: (2019)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
por: Ong, F., et al.
Publicado: (2022)

Rational Combinations of Targeted Agents in AML
por: Bose, Prithviraj, et al.
Publicado: (2015)

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
por: Bose, Prithviraj, et al.
Publicado: (2023)

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy
por: Abbas, Hussein A., et al.
Publicado: (2021)

Extramedullary Acute Myeloid Leukemia: Leukemic Pleural Effusion, Case Report and Review of the Literature
por: Pemmaraju, Naveen, et al.
Publicado: (2014)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
por: Abbas, Hussein A., et al.
Publicado: (2022)

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
por: Alotaibi, Ahmad S., et al.
Publicado: (2020)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
por: Bose, Prithviraj, et al.
Publicado: (2019)

Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature
por: Volpe, Giacomo, et al.
Publicado: (2017)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Coordinate PI3K pathway and Bcl-2 family disruption in AML
por: Bose, Prithviraj, et al.
Publicado: (2012)

STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML
por: Oancea, Claudia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4jfesu832ou3hkd70fq0nckmj6